 Connection
Mayumi Nakagawa to Adult
This is a "connection" page, showing publications Mayumi Nakagawa has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.592 |
|
|
|
-
Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299.
Score: 0.066
-
Shah SK, Demmings BE, Bimali M, Hadden K, Nakagawa M. Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures. Cancer Control. 2021 Jan-Dec; 28:10732748211037908.
Score: 0.062
-
Ravilla R, Coleman HN, Chow CE, Chan L, Fuhrman BJ, Greenfield WW, Robeson MS, Iverson K, Spencer H, Nakagawa M. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419893063.
Score: 0.054
-
Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73.
Score: 0.045
-
Stratton SL, Spencer HJ, Greenfield WW, Low G, Hitt WC, Quick CM, Jeffus SK, Blackmon V, Nakagawa M. A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. Clin Trials. 2015 Jun; 12(3):199-204.
Score: 0.041
-
Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc. 2013 Jan; 109(8):160-3.
Score: 0.036
-
Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70.
Score: 0.033
-
Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec; 146(12):1431-3.
Score: 0.031
-
Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9.
Score: 0.030
-
Kim KH, Greenfield W, Shotts E, Nakagawa M. Detection of human papillomavirus type 16-specific T lymphocytes by a recombinant vaccinia virus-based enzyme-linked immunospot assay. Clin Vaccine Immunol. 2007 Apr; 14(4):362-8.
Score: 0.024
-
Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5.
Score: 0.021
-
Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion. 2004 Dec; 44(12):1683-8.
Score: 0.020
-
Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion. 2004 Dec; 44(12):1689-94.
Score: 0.020
-
Nakagawa M, Dempsey DA, Haller C, Toy P. Safe lead levels: blood transfusion of extremely low birth weight infants. Clin Pediatr (Phila). 2004 Sep; 43(7):681.
Score: 0.020
-
Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82.
Score: 0.017
-
Shibata T, Nakagawa M, Coleman HN, Owens SM, Greenfield WW, Sasagawa T, Robeson MS. Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota. PLoS One. 2021; 16(8):e0237556.
Score: 0.016
-
Matsumoto T, Oda Y, Hasegawa Y, Hashimura M, Oguri Y, Inoue H, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma. Am J Pathol. 2021 10; 191(10):1837-1850.
Score: 0.016
-
Matsumoto T, Chino H, Akiya M, Hashimura M, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Mol Carcinog. 2020 12; 59(12):1409-1419.
Score: 0.015
-
Kamiya T, Hira D, Hoshino N, Kurihara M, Nakagawa M, Sasaki M, Terada T. Low Body Mass Index and Myeloablative Conditioning Regimen Prolong the Duration of Parenteral Nutrition During Hematopoietic Stem Cell Transplantation. Ann Nutr Metab. 2019; 74(2):107-114.
Score: 0.014
-
Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|